Brands, Medical Use, Clinical Data
Drug Category
- Immunomodulatory Agents
- Immunosuppresants
Dosage Forms
Brands / Synonyms
Amevive; Amevive (Biogen Inc.)
Description
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Indications
For treatment of moderate to severe chronic plaque psoriasis
Pharmacology
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.
Mechanism of Action
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.
Absorption
Not Available
Toxicity
Not Available
Biotrnasformation / Drug Metabolism
Not Available
Contraindications
Not Available
Drug Interactions
Not Available
|
